- Home
- MTZ vs INCY Comparison
MTZ vs INCY Comparison
Compare MTZ & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTZ
- INCY
- Stock Information
- Founded
- MTZ 1929
- INCY 1991
- Country
- MTZ United States
- INCY United States
- Employees
- MTZ N/A
- INCY N/A
- Industry
- MTZ Water Sewer Pipeline Comm & Power Line Construction
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- MTZ Industrials
- INCY Health Care
- Exchange
- MTZ Nasdaq
- INCY Nasdaq
- Market Cap
- MTZ 13.6B
- INCY 13.0B
- IPO Year
- MTZ N/A
- INCY 1993
- Fundamental
- Price
- MTZ $195.24
- INCY $84.92
- Analyst Decision
- MTZ Strong Buy
- INCY Buy
- Analyst Count
- MTZ 21
- INCY 20
- Target Price
- MTZ $188.95
- INCY $80.31
- AVG Volume (30 Days)
- MTZ 897.7K
- INCY 1.6M
- Earning Date
- MTZ 10-30-2025
- INCY 10-28-2025
- Dividend Yield
- MTZ N/A
- INCY N/A
- EPS Growth
- MTZ 3211.19
- INCY 900.04
- EPS
- MTZ 3.34
- INCY 4.37
- Revenue
- MTZ $13,047,952,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- MTZ $14.77
- INCY $16.26
- Revenue Next Year
- MTZ $8.96
- INCY $11.07
- P/E Ratio
- MTZ $57.86
- INCY $19.38
- Revenue Growth
- MTZ 7.08
- INCY 18.87
- 52 Week Low
- MTZ $99.70
- INCY $53.56
- 52 Week High
- MTZ $198.48
- INCY $87.99
- Technical
- Relative Strength Index (RSI)
- MTZ 65.52
- INCY 55.83
- Support Level
- MTZ $173.90
- INCY $82.72
- Resistance Level
- MTZ $198.48
- INCY $85.98
- Average True Range (ATR)
- MTZ 5.78
- INCY 1.84
- MACD
- MTZ 1.42
- INCY -0.61
- Stochastic Oscillator
- MTZ 88.19
- INCY 41.75
About MTZ MasTec Inc.
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. The company's primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.